Clinical Trials
7 trialsNCT01647165 2019-12-12
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT00334932 2014-01-10
Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00389701 2014-01-10
Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00742404 2013-12-18
Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00317811 2013-11-06
Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00316940 2013-09-20
Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00438841 2009-03-13
Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Unknown